A*STAR & Cytos Biotechnology Collaborate on Influenza Vaccine

摘要

Switzerland's Cytos Biotechnology and Singapore's Agency for Science, Technology and Research (A*STAR) jointly announced today their first collaboration on a virus-like particle (VLP) vaccine. This partnership, which involves academic and clinical partners across Singapore , aims at research, development and commercialization of a VLP vaccine to manage influenza infections. This collaboration could potentially secure an independent supply of vaccines for Singapore and other ASEAN countries to protect against seasonal influenza and future pandemics and extends Cytos' R&D pipeline.